Current Challenges in Treating Unresectable Hepatocellular Carcinoma
For a decade, sorafenib was the only available treatment option for patients with unresectable hepatocellular carcinoma (HCC). The surge in systemic therapies for the treatment of HCC patients over the past five years resulted in significantly prolonged survival and improved quality of life. However...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2023.18.127 |